Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval
Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.
Capricor is waiting for the FDA (the government group that approves medicines) to say yes to their new treatment, and the company says it has enough money in the bank to keep going. When a company feels ready and has cash saved up, it's a sign they believe in what they're making.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.